Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies.

Drug Category : Array
Conference Category : Array
Lead Author : Nastoupil L, et al.
Published Date : 20/06/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Triplet%20Phase%20I%20Loretta%20Lugano%202015.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top